<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00959049</url>
  </required_header>
  <id_info>
    <org_study_id>CSLCT-USF-07-36</org_study_id>
    <nct_id>NCT00959049</nct_id>
  </id_info>
  <brief_title>A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population</brief_title>
  <official_title>A Phase III, Randomized, Observer-blind, Multi-center, Noninferiority Comparison of the Immune Response of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Trivalent Inactivated Split-Virion Influenza Vaccine in a Pediatric Population Aged Greater Than or Equal to 6 Months to Less Than 18 Years.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seqirus</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seqirus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the immunogenicity and safety profile of CSL
      Limited's Influenza Virus Vaccine compared to a US licensed comparator Influenza Virus
      Vaccine in a pediatric population aged greater than or equal to 6 months to less than 18
      years.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Titer 30 Days After the Last Study Vaccination</measure>
    <time_frame>30 days after the last study vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Seroconversion 30 Days After the Last Study Vaccination</measure>
    <time_frame>30 days after the last study vaccination</time_frame>
    <description>Seroconversion rate was defined as the proportion of participants with either a titer of less than 1:10 before vaccination achieving a HI antibody titer of 1:40 or more after vaccination, or a HI titer of 1:10 or more before vaccination achieving a four-fold or greater increase in HI titer after vaccination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency and Intensity of Local and Systemic Solicited Symptoms, Cohort A (6 Months to &lt; 3 Years)</measure>
    <time_frame>7 days after each vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and Intensity of Local and Systemic Solicited Symptoms, Cohort B</measure>
    <time_frame>7 days after each vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and Intensity of Local and Systemic Solicited Symptoms, Cohort C</measure>
    <time_frame>7 days after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and Intensity of Unsolicited Adverse Events (UAEs)</measure>
    <time_frame>30 days after each vaccination</time_frame>
    <description>UAE stands for Unsolicited Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New Onset of Chronic Illnesses (NOCIs)</measure>
    <time_frame>6 months after last study vaccination</time_frame>
    <description>New onset of chronic illness after any vaccine dose. A new onset of chronic illness was defined as the diagnosis of a new medical condition which was chronic in nature, including those potentially controllable by medication (e.g., diabetes, asthma).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events (SAEs)</measure>
    <time_frame>6 months after last study vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Local and Systemic Solicited Symptoms, Cohort A (6 Months to &lt; 3 Years)</measure>
    <time_frame>7 days after each vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Local and Systemic Solicited Symptoms, Cohort B</measure>
    <time_frame>7 days after each vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Local and Systemic Solicited Symptoms, Cohort C</measure>
    <time_frame>7 days after vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">1474</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Afluria Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Age 6 months to &lt; 3 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Afluria Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Age 3 to &lt; 9 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Afluria Cohort C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Age 9 to &lt; 18 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluzone Cohort A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Age 6 months to &lt; 3 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluzone Cohort B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Age 3 to &lt; 9 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluzone Cohort C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Age 9 to &lt; 18 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CSL's Influenza Virus Vaccine (Afluria)</intervention_name>
    <description>0.25 mL (one or two doses) or 0.5 mL (one or two doses) by intramuscular injection as directed by immunization guidelines</description>
    <arm_group_label>Afluria Cohort A</arm_group_label>
    <arm_group_label>Afluria Cohort B</arm_group_label>
    <arm_group_label>Afluria Cohort C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza Virus Vaccine (Fluzone)</intervention_name>
    <description>0.25 mL (one or two doses) or 0.5 mL (one or two doses) by intramuscular injection as directed by immunization guidelines</description>
    <arm_group_label>Fluzone Cohort A</arm_group_label>
    <arm_group_label>Fluzone Cohort B</arm_group_label>
    <arm_group_label>Fluzone Cohort C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or non-pregnant female participants aged ≥ 6 calendar months to &lt; 18
             years at the time of the first study vaccination.

          -  For participants aged ≥ 6 months to &lt; 9 years, born after a normal gestation period
             (between 36 and 42 weeks).

          -  Females of childbearing potential (i.e., ovulating, pre-menopausal, not surgically
             sterile) must be abstinent or be willing to use a medically accepted contraceptive
             regimen for at least 2 months after vaccination. Females aged ≥ 9 years must also
             return a negative urine pregnancy test at enrollment.

        Exclusion Criteria:

          -  Known hypersensitivity to a previous dose of influenza vaccine or allergy to eggs,
             chicken protein, neomycin, polymyxin, or any components of the Study Vaccine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Director Vaccines</last_name>
    <role>Study Director</role>
    <affiliation>Seqirus</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Harrisburg</city>
        <state>Arkansas</state>
        <zip>72432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mountain Home</city>
        <state>Arkansas</state>
        <zip>72653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32935</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bardstown</city>
        <state>Kentucky</state>
        <zip>40004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Binghamton</city>
        <state>New York</state>
        <zip>13901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elmira</city>
        <state>New York</state>
        <zip>14901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center- Division of Infectious Disease</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warr Acres</city>
        <state>Oklahoma</state>
        <zip>73132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC / Community Medicine Inc</name>
      <address>
        <city>Greenville</city>
        <state>Pennsylvania</state>
        <zip>16125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Associates of Latrobe</name>
      <address>
        <city>Latrobe</city>
        <state>Pennsylvania</state>
        <zip>15650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Alliance Greentree Division</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Hills Pediatrics</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>South Jordan</city>
        <state>Utah</state>
        <zip>84095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burke</city>
        <state>Virginia</state>
        <zip>22015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vienna</city>
        <state>Virginia</state>
        <zip>22180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2009</study_first_submitted>
  <study_first_submitted_qc>August 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2009</study_first_posted>
  <results_first_submitted>July 3, 2011</results_first_submitted>
  <results_first_submitted_qc>July 3, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 29, 2011</results_first_posted>
  <last_update_submitted>April 16, 2017</last_update_submitted>
  <last_update_submitted_qc>April 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled into this study during the autumn of 2009 at 23 sites in the US.</recruitment_details>
      <pre_assignment_details>A total of 1474 participants were enrolled, vaccinated and analyzed.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Afluria Cohort A</title>
          <description>Age 6 months to &lt; 3 years. Participants received one of two doses of the 2009/2010 influenza season formulation of Afluria.</description>
        </group>
        <group group_id="P2">
          <title>Afluria Cohort B</title>
          <description>Age 3 to &lt; 9 years. Participants received one or two doses of the 2009/2010 influenza season formulation of Afluria.</description>
        </group>
        <group group_id="P3">
          <title>Afluria Cohort C</title>
          <description>Age 9 to &lt; 18 years. Participants received one or two doses of the 2009/2010 influenza season formulation of Afluria.</description>
        </group>
        <group group_id="P4">
          <title>Fluzone Cohort A</title>
          <description>Age 6 months to &lt; 3 years. Participants received one of two doses of the 2009/2010 influenza season formulation of Fluzone.</description>
        </group>
        <group group_id="P5">
          <title>Fluzone Cohort B</title>
          <description>Age 3 to &lt; 9 years. Participants received one of two doses of the 2009/2010 influenza season formulation of Fluzone.</description>
        </group>
        <group group_id="P6">
          <title>Fluzone Cohort C</title>
          <description>Age 9 to &lt; 18 years. Participants received one of two doses of the 2009/2010 influenza season formulation of Fluzone.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="231"/>
                <participants group_id="P2" count="254"/>
                <participants group_id="P3" count="254"/>
                <participants group_id="P4" count="228"/>
                <participants group_id="P5" count="257"/>
                <participants group_id="P6" count="250"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="213"/>
                <participants group_id="P2" count="247"/>
                <participants group_id="P3" count="253"/>
                <participants group_id="P4" count="217"/>
                <participants group_id="P5" count="248"/>
                <participants group_id="P6" count="249"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Contraindicated medication</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Afluria Cohort A</title>
          <description>Age 6 months to &lt; 3 years. Participants received one of two doses of the 2009/2010 influenza season formulation of Afluria.</description>
        </group>
        <group group_id="B2">
          <title>Afluria Cohort B</title>
          <description>Age 3 to &lt; 9 years. Participants received one or two doses of the 2009/2010 influenza season formulation of Afluria.</description>
        </group>
        <group group_id="B3">
          <title>Afluria Cohort C</title>
          <description>Age 9 to &lt; 18 years. Participants received one or two doses of the 2009/2010 influenza season formulation of Afluria.</description>
        </group>
        <group group_id="B4">
          <title>Fluzone Cohort A</title>
          <description>Age 6 months to &lt; 3 years. Participants received one of two doses of the 2009/2010 influenza season formulation of Fluzone.</description>
        </group>
        <group group_id="B5">
          <title>Fluzone Cohort B</title>
          <description>Age 3 to &lt; 9 years. Participants received one of two doses of the 2009/2010 influenza season formulation of Fluzone.</description>
        </group>
        <group group_id="B6">
          <title>Fluzone Cohort C</title>
          <description>Age 9 to &lt; 18 years. Participants received one of two doses of the 2009/2010 influenza season formulation of Fluzone.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="231"/>
            <count group_id="B2" value="254"/>
            <count group_id="B3" value="254"/>
            <count group_id="B4" value="228"/>
            <count group_id="B5" value="257"/>
            <count group_id="B6" value="250"/>
            <count group_id="B7" value="1474"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="231"/>
                    <measurement group_id="B2" value="254"/>
                    <measurement group_id="B3" value="254"/>
                    <measurement group_id="B4" value="228"/>
                    <measurement group_id="B5" value="257"/>
                    <measurement group_id="B6" value="250"/>
                    <measurement group_id="B7" value="1474"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.94" spread="0.667"/>
                    <measurement group_id="B2" value="5.93" spread="1.725"/>
                    <measurement group_id="B3" value="12.98" spread="2.388"/>
                    <measurement group_id="B4" value="1.96" spread="0.673"/>
                    <measurement group_id="B5" value="5.82" spread="1.748"/>
                    <measurement group_id="B6" value="12.86" spread="2.474"/>
                    <measurement group_id="B7" value="7.06" spread="4.855"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="140"/>
                    <measurement group_id="B3" value="121"/>
                    <measurement group_id="B4" value="101"/>
                    <measurement group_id="B5" value="127"/>
                    <measurement group_id="B6" value="120"/>
                    <measurement group_id="B7" value="728"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="112"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="133"/>
                    <measurement group_id="B4" value="127"/>
                    <measurement group_id="B5" value="130"/>
                    <measurement group_id="B6" value="130"/>
                    <measurement group_id="B7" value="746"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="231"/>
                    <measurement group_id="B2" value="254"/>
                    <measurement group_id="B3" value="254"/>
                    <measurement group_id="B4" value="228"/>
                    <measurement group_id="B5" value="257"/>
                    <measurement group_id="B6" value="250"/>
                    <measurement group_id="B7" value="1474"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Frequency and Intensity of Local and Systemic Solicited Symptoms, Cohort A (6 Months to &lt; 3 Years)</title>
        <time_frame>7 days after each vaccination</time_frame>
        <population>Safety population; Afluria Cohort A receiving 2 doses N=96, Fluzone Cohort A receiving 2 doses N=110</population>
        <group_list>
          <group group_id="O1">
            <title>Afluria Cohort A</title>
            <description>Age 6 months to &lt; 3 years</description>
          </group>
          <group group_id="O2">
            <title>Fluzone Cohort A</title>
            <description>Age 6 months to &lt; 3 years</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency and Intensity of Local and Systemic Solicited Symptoms, Cohort A (6 Months to &lt; 3 Years)</title>
          <population>Safety population; Afluria Cohort A receiving 2 doses N=96, Fluzone Cohort A receiving 2 doses N=110</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
                <count group_id="O2" value="228"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any local solicited symptom post-dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any pain (post dose 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 pain (post dose 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any redness (&gt; 0 mm) (post dose 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 redness (&gt; 30 mm) (post dose 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any swelling (&gt; 0 mm) (post dose 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 swelling (&gt; 30 mm) (post dose 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any local solicited symptom post-dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any pain (post dose 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 pain (post dose 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any redness (&gt; 0 mm) (post dose 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 redness (&gt; 30 mm) (post dose 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any swelling (&gt; 0 mm) (post dose 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 swelling (&gt; 30 mm) (post dose 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any systemic solicited symptom, post dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171"/>
                    <measurement group_id="O2" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any fever ≥ 99.5°F ax or≥ 100.4°F oral, dose1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 fever &gt; 103.1°F ax or&gt; 104.0°F oral, dose1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any nausea/vomiting, dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 nausea/vomiting prevented activities,dose1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any diarrhea, dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 diarrhea prevented activities, dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any loss of appetite, dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade3 loss of appetite prevented activities dose1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any irritability, dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 irritability prevented activities dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any systemic solicited symptom post-dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any fever ≥ 99.5°F ax or≥ 100.4°F oral, dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 fever &gt; 103.1°F ax or&gt; 104.0°F oral, dose2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any nausea/vomiting, dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade3 nausea/vomiting prevented activities, dose2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any diarrhea, dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade3 diarrhea (prevented activities), dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any loss of appetite, dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade3 loss of appetite prevented activities dose2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any irritability, dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 irritability prevented activities, dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency and Intensity of Local and Systemic Solicited Symptoms, Cohort B</title>
        <time_frame>7 days after each vaccination</time_frame>
        <population>Safety population; Afluria cohort B receiving 2 doses N=68, Fluzone cohort B receiving 2 doses N=78</population>
        <group_list>
          <group group_id="O1">
            <title>Afluria Cohort B</title>
            <description>Age 3 to &lt; 9 years</description>
          </group>
          <group group_id="O2">
            <title>Fluzone Cohort B</title>
            <description>Age 3 to &lt; 9 years</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency and Intensity of Local and Systemic Solicited Symptoms, Cohort B</title>
          <population>Safety population; Afluria cohort B receiving 2 doses N=68, Fluzone cohort B receiving 2 doses N=78</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="252"/>
                <count group_id="O2" value="255"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any local solicited symptom post-dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164"/>
                    <measurement group_id="O2" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any pain, post dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149"/>
                    <measurement group_id="O2" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 pain, post dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any redness (&gt; 0 mm), post dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 redness (&gt; 30 mm), post dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any swelling (&gt; 0 mm), post dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 swelling (&gt; 30 mm), post dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any local solicited symptom post-dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any pain, post dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 pain, post dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any redness (&gt; 0 mm), post dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 redness (&gt; 30 mm), post dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any swelling (&gt; 0 mm), post dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 swelling (&gt; 30 mm), post dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any systemic solicited symptom post-dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140"/>
                    <measurement group_id="O2" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any fever ≥ 99.5°F ax or ≥ 100.4°F oral, dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 fever &gt; 103.1°F ax or &gt; 104.0°F oral dose1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any nausea/vomiting, dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade3 nausea/vomiting prevented activities, dose1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any diarrhea, dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 diarrhea (prevented activities), dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any malaise, dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 malaise (prevented activities), dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any headache, dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 headache (prevented activities), dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any myalgia, dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 myalgia (prevented activities), dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any systemic solicited symptom post-dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any fever ≥ 99.5°F ax or ≥ 100.4°F oral dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade3 fever &gt; 103.1°F ax or&gt; 104.0°F oral, dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any nausea/vomiting, dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade3 nausea/vomiting prevented activities ,dose2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any diarrhea, dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 diarrhea (prevented activities), dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any malaise, dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 malaise (prevented activities), dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any headache, dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 headache (prevented activities), dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any myalgia, dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 myalgia (prevented activities), dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency and Intensity of Local and Systemic Solicited Symptoms, Cohort C</title>
        <time_frame>7 days after vaccination</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Afluria Cohort C</title>
            <description>Age 9 to &lt; 18 years</description>
          </group>
          <group group_id="O2">
            <title>Fluzone Cohort C</title>
            <description>Age 9 to &lt; 18 years</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency and Intensity of Local and Systemic Solicited Symptoms, Cohort C</title>
          <population>Safety population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="254"/>
                <count group_id="O2" value="250"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any local solicited symptom post-dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174"/>
                    <measurement group_id="O2" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167"/>
                    <measurement group_id="O2" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 pain (prevented activities)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any redness (&gt; 0 mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 redness (&gt; 30 mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any swelling (&gt; 0 mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 swelling (&gt; 30 mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any systemic solicited symptom post-dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144"/>
                    <measurement group_id="O2" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any fever (≥ 99.5°F ax or ≥ 100.4°F oral)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 fever (&gt; 103.1°F ax or &gt; 104.0°F oral)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any nausea/vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 nausea/vomiting (prevented activities)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 diarrhea (prevented activities)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 malaise (prevented activities)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 headache (prevented activities)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 myalgia (prevented activities)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titer 30 Days After the Last Study Vaccination</title>
        <time_frame>30 days after the last study vaccination</time_frame>
        <population>Per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Afluria Cohort A</title>
            <description>Age 6 months to &lt; 3 years. Participants received one of two doses of the 2009/2010 influenza season formulation of Afluria.</description>
          </group>
          <group group_id="O2">
            <title>Afluria Cohort B</title>
            <description>Age 3 to &lt; 9 years. Participants received one or two doses of the 2009/2010 influenza season formulation of Afluria.</description>
          </group>
          <group group_id="O3">
            <title>Afluria Cohort C</title>
            <description>Age 9 to &lt; 18 years. Participants received one or two doses of the 2009/2010 influenza season formulation of Afluria.</description>
          </group>
          <group group_id="O4">
            <title>Fluzone Cohort A</title>
            <description>Age 6 months to &lt; 3 years. Participants received one of two doses of the 2009/2010 influenza season formulation of Fluzone.</description>
          </group>
          <group group_id="O5">
            <title>Fluzone Cohort B</title>
            <description>Age 3 to &lt; 9 years. Participants received one of two doses of the 2009/2010 influenza season formulation of Fluzone.</description>
          </group>
          <group group_id="O6">
            <title>Fluzone Cohort C</title>
            <description>Age 9 to &lt; 18 years. Participants received one of two doses of the 2009/2010 influenza season formulation of Fluzone.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer 30 Days After the Last Study Vaccination</title>
          <population>Per-protocol population</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="229"/>
                <count group_id="O3" value="230"/>
                <count group_id="O4" value="201"/>
                <count group_id="O5" value="236"/>
                <count group_id="O6" value="233"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 (A/Brisbane/59/2007)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="235.44" lower_limit="199.67" upper_limit="277.61"/>
                    <measurement group_id="O2" value="345.50" lower_limit="295.54" upper_limit="403.92"/>
                    <measurement group_id="O3" value="652.99" lower_limit="566.91" upper_limit="752.14"/>
                    <measurement group_id="O4" value="227.19" lower_limit="188.39" upper_limit="273.98"/>
                    <measurement group_id="O5" value="351.88" lower_limit="303.29" upper_limit="408.25"/>
                    <measurement group_id="O6" value="652.17" lower_limit="569.59" upper_limit="746.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 ( A/Uruguay/716/2007)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="309.19" lower_limit="253.49" upper_limit="377.13"/>
                    <measurement group_id="O2" value="909.22" lower_limit="772.67" upper_limit="1069.90"/>
                    <measurement group_id="O3" value="948.86" lower_limit="824.88" upper_limit="1091.46"/>
                    <measurement group_id="O4" value="340.49" lower_limit="283.98" upper_limit="408.25"/>
                    <measurement group_id="O5" value="870.34" lower_limit="751.62" upper_limit="1007.80"/>
                    <measurement group_id="O6" value="1069.7" lower_limit="934.77" upper_limit="1224.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (B/Brisbane/60/2008)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.46" lower_limit="59.32" upper_limit="90.97"/>
                    <measurement group_id="O2" value="122.71" lower_limit="102.55" upper_limit="146.83"/>
                    <measurement group_id="O3" value="107.92" lower_limit="71.77" upper_limit="126.91"/>
                    <measurement group_id="O4" value="57.92" lower_limit="46.92" upper_limit="71.49"/>
                    <measurement group_id="O5" value="104.91" lower_limit="88.67" upper_limit="123.42"/>
                    <measurement group_id="O6" value="126.99" lower_limit="107.53" upper_limit="149.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Seroconversion 30 Days After the Last Study Vaccination</title>
        <description>Seroconversion rate was defined as the proportion of participants with either a titer of less than 1:10 before vaccination achieving a HI antibody titer of 1:40 or more after vaccination, or a HI titer of 1:10 or more before vaccination achieving a four-fold or greater increase in HI titer after vaccination.</description>
        <time_frame>30 days after the last study vaccination</time_frame>
        <population>Per-Protocol Population</population>
        <group_list>
          <group group_id="O1">
            <title>Afluria Cohort A</title>
            <description>Age 6 months to &lt; 3 years. Participants received one of two doses of the 2009/2010 influenza season formulation of Afluria.</description>
          </group>
          <group group_id="O2">
            <title>Afluria Cohort B</title>
            <description>Age 3 to &lt; 9 years. Participants received one or two doses of the 2009/2010 influenza season formulation of Afluria.</description>
          </group>
          <group group_id="O3">
            <title>Afluria Cohort C</title>
            <description>Age 9 to &lt; 18 years. Participants received one or two doses of the 2009/2010 influenza season formulation of Afluria.</description>
          </group>
          <group group_id="O4">
            <title>Fluzone Cohort A</title>
            <description>Age 6 months to &lt; 3 years. Participants received one of two doses of the 2009/2010 influenza season formulation of Fluzone.</description>
          </group>
          <group group_id="O5">
            <title>Fluzone Cohort B</title>
            <description>Age 3 to &lt; 9 years. Participants received one of two doses of the 2009/2010 influenza season formulation of Fluzone.</description>
          </group>
          <group group_id="O6">
            <title>Fluzone Cohort C</title>
            <description>Age 9 to &lt; 18 years. Participants received one of two doses of the 2009/2010 influenza season formulation of Fluzone.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion 30 Days After the Last Study Vaccination</title>
          <description>Seroconversion rate was defined as the proportion of participants with either a titer of less than 1:10 before vaccination achieving a HI antibody titer of 1:40 or more after vaccination, or a HI titer of 1:10 or more before vaccination achieving a four-fold or greater increase in HI titer after vaccination.</description>
          <population>Per-Protocol Population</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="229"/>
                <count group_id="O3" value="230"/>
                <count group_id="O4" value="201"/>
                <count group_id="O5" value="236"/>
                <count group_id="O6" value="233"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 (A/Brisbane/59/2007)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84" lower_limit="78" upper_limit="89"/>
                    <measurement group_id="O2" value="66" lower_limit="59" upper_limit="72"/>
                    <measurement group_id="O3" value="64" lower_limit="57" upper_limit="70"/>
                    <measurement group_id="O4" value="74" lower_limit="67" upper_limit="80"/>
                    <measurement group_id="O5" value="64" lower_limit="58" upper_limit="70"/>
                    <measurement group_id="O6" value="61" lower_limit="55" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 ( A/Uruguay/716/2007)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="77" upper_limit="88"/>
                    <measurement group_id="O2" value="71" lower_limit="65" upper_limit="77"/>
                    <measurement group_id="O3" value="72" lower_limit="66" upper_limit="78"/>
                    <measurement group_id="O4" value="85" lower_limit="79" upper_limit="90"/>
                    <measurement group_id="O5" value="74" lower_limit="68" upper_limit="80"/>
                    <measurement group_id="O6" value="73" lower_limit="66" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (B/Brisbane/60/2008)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67" lower_limit="60" upper_limit="73"/>
                    <measurement group_id="O2" value="73" lower_limit="67" upper_limit="79"/>
                    <measurement group_id="O3" value="67" lower_limit="31" upper_limit="73"/>
                    <measurement group_id="O4" value="61" lower_limit="54" upper_limit="68"/>
                    <measurement group_id="O5" value="76" lower_limit="70" upper_limit="82"/>
                    <measurement group_id="O6" value="73" lower_limit="67" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency and Intensity of Unsolicited Adverse Events (UAEs)</title>
        <description>UAE stands for Unsolicited Adverse Events</description>
        <time_frame>30 days after each vaccination</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Afluria Cohort A</title>
            <description>Age 6 months to &lt; 3 years. Participants received one of two doses of the 2009/2010 influenza season formulation of Afluria.</description>
          </group>
          <group group_id="O2">
            <title>Afluria Cohort B</title>
            <description>Age 3 to &lt; 9 years. Participants received one or two doses of the 2009/2010 influenza season formulation of Afluria.</description>
          </group>
          <group group_id="O3">
            <title>Afluria Cohort C</title>
            <description>Age 9 to &lt; 18 years. Participants received one or two doses of the 2009/2010 influenza season formulation of Afluria.</description>
          </group>
          <group group_id="O4">
            <title>Fluzone Cohort A</title>
            <description>Age 6 months to &lt; 3 years. Participants received one of two doses of the 2009/2010 influenza season formulation of Fluzone.</description>
          </group>
          <group group_id="O5">
            <title>Fluzone Cohort B</title>
            <description>Age 3 to &lt; 9 years. Participants received one of two doses of the 2009/2010 influenza season formulation of Fluzone.</description>
          </group>
          <group group_id="O6">
            <title>Fluzone Cohort C</title>
            <description>Age 9 to &lt; 18 years. Participants received one of two doses of the 2009/2010 influenza season formulation of Fluzone.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency and Intensity of Unsolicited Adverse Events (UAEs)</title>
          <description>UAE stands for Unsolicited Adverse Events</description>
          <population>Safety population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
                <count group_id="O2" value="252"/>
                <count group_id="O3" value="254"/>
                <count group_id="O4" value="228"/>
                <count group_id="O5" value="255"/>
                <count group_id="O6" value="250"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="88"/>
                    <measurement group_id="O4" value="112"/>
                    <measurement group_id="O5" value="84"/>
                    <measurement group_id="O6" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="22"/>
                    <measurement group_id="O6" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>New Onset of Chronic Illnesses (NOCIs)</title>
        <description>New onset of chronic illness after any vaccine dose. A new onset of chronic illness was defined as the diagnosis of a new medical condition which was chronic in nature, including those potentially controllable by medication (e.g., diabetes, asthma).</description>
        <time_frame>6 months after last study vaccination</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Afluria Cohort A</title>
            <description>Age 6 months to &lt; 3 years. Participants received one of two doses of the 2009/2010 influenza season formulation of Afluria.</description>
          </group>
          <group group_id="O2">
            <title>Afluria Cohort B</title>
            <description>Age 3 to &lt; 9 years. Participants received one or two doses of the 2009/2010 influenza season formulation of Afluria.</description>
          </group>
          <group group_id="O3">
            <title>Afluria Cohort C</title>
            <description>Age 9 to &lt; 18 years. Participants received one or two doses of the 2009/2010 influenza season formulation of Afluria.</description>
          </group>
          <group group_id="O4">
            <title>Fluzone Cohort A</title>
            <description>Age 6 months to &lt; 3 years. Participants received one of two doses of the 2009/2010 influenza season formulation of Fluzone.</description>
          </group>
          <group group_id="O5">
            <title>Fluzone Cohort B</title>
            <description>Age 3 to &lt; 9 years. Participants received one of two doses of the 2009/2010 influenza season formulation of Fluzone.</description>
          </group>
          <group group_id="O6">
            <title>Fluzone Cohort C</title>
            <description>Age 9 to &lt; 18 years. Participants received one of two doses of the 2009/2010 influenza season formulation of Fluzone.</description>
          </group>
        </group_list>
        <measure>
          <title>New Onset of Chronic Illnesses (NOCIs)</title>
          <description>New onset of chronic illness after any vaccine dose. A new onset of chronic illness was defined as the diagnosis of a new medical condition which was chronic in nature, including those potentially controllable by medication (e.g., diabetes, asthma).</description>
          <population>Safety population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
                <count group_id="O2" value="252"/>
                <count group_id="O3" value="254"/>
                <count group_id="O4" value="228"/>
                <count group_id="O5" value="255"/>
                <count group_id="O6" value="250"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total number of participants with NOCI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of participants with related NOCI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asthma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Von Willebrand's Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eczema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Attention deficit disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serious Adverse Events (SAEs)</title>
        <time_frame>6 months after last study vaccination</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Afluria Cohort A</title>
            <description>Age 6 months to &lt; 3 years</description>
          </group>
          <group group_id="O2">
            <title>Afluria Cohort B</title>
            <description>Age 3 to &lt; 9 years</description>
          </group>
          <group group_id="O3">
            <title>Afluria Cohort C</title>
            <description>Age 9 to &lt; 18 years</description>
          </group>
          <group group_id="O4">
            <title>Fluzone Cohort A</title>
            <description>Age 6 months to &lt; 3 years</description>
          </group>
          <group group_id="O5">
            <title>Fluzone Cohort B</title>
            <description>Age 3 to &lt; 9 years</description>
          </group>
          <group group_id="O6">
            <title>Fluzone Cohort C</title>
            <description>Age 3 to &lt; 9 years</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Adverse Events (SAEs)</title>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
                <count group_id="O2" value="252"/>
                <count group_id="O3" value="254"/>
                <count group_id="O4" value="228"/>
                <count group_id="O5" value="255"/>
                <count group_id="O6" value="250"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of participants with SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of participants with related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Local and Systemic Solicited Symptoms, Cohort A (6 Months to &lt; 3 Years)</title>
        <time_frame>7 days after each vaccination</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Afluria Cohort A</title>
            <description>Age 6 months to &lt; 3 years</description>
          </group>
          <group group_id="O2">
            <title>Fluzone Cohort A</title>
            <description>Age 6 months to &lt; 3 years</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Local and Systemic Solicited Symptoms, Cohort A (6 Months to &lt; 3 Years)</title>
          <population>Safety population</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
                <count group_id="O2" value="228"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any pain post-dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.57" spread="0.952"/>
                    <measurement group_id="O2" value="1.43" spread="0.728"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any redness (&gt; 0 mm), post dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.09" spread="1.405"/>
                    <measurement group_id="O2" value="2.22" spread="1.939"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any swelling (&gt; 0 mm), post dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.13" spread="2.930"/>
                    <measurement group_id="O2" value="2.00" spread="1.569"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any pain post-dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.54" spread="0.793"/>
                    <measurement group_id="O2" value="1.45" spread="0.739"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any redness (&gt; 0 mm), post dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.80" spread="1.014"/>
                    <measurement group_id="O2" value="1.73" spread="0.935"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any swelling (&gt; 0 mm), post dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" spread="0.707"/>
                    <measurement group_id="O2" value="1.57" spread="0.787"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any fever dose 1 (≥ 99.5°F ax or ≥ 100.4°F oral)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.38" spread="0.869"/>
                    <measurement group_id="O2" value="1.49" spread="0.989"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any nausea/vomiting, post dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" spread="1.119"/>
                    <measurement group_id="O2" value="1.29" spread="1.042"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any diarrhea, post dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.23" spread="2.157"/>
                    <measurement group_id="O2" value="2.16" spread="2.189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any loss of appetite, post dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.61" spread="3.695"/>
                    <measurement group_id="O2" value="2.85" spread="4.458"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any irritability, post dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.26" spread="2.858"/>
                    <measurement group_id="O2" value="2.64" spread="3.825"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any fever dose 2 (≥ 99.5°F ax or ≥ 100.4°F oral)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.80" spread="1.146"/>
                    <measurement group_id="O2" value="1.81" spread="1.559"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any nausea/vomiting, post dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.50" spread="1.291"/>
                    <measurement group_id="O2" value="1.78" spread="1.093"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any diarrhea, post dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.83" spread="2.431"/>
                    <measurement group_id="O2" value="2.44" spread="2.332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any loss of appetite, post dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.47" spread="1.586"/>
                    <measurement group_id="O2" value="2.33" spread="1.447"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any irritability, post dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.31" spread="1.732"/>
                    <measurement group_id="O2" value="2.17" spread="1.543"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Local and Systemic Solicited Symptoms, Cohort B</title>
        <time_frame>7 days after each vaccination</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Afluria Cohort B</title>
            <description>Age 3 to &lt; 9 years</description>
          </group>
          <group group_id="O2">
            <title>Fluzone Cohort B</title>
            <description>Age 3 to &lt; 9 years</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Local and Systemic Solicited Symptoms, Cohort B</title>
          <population>Safety population</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="252"/>
                <count group_id="O2" value="255"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any pain post-dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.89" spread="1.138"/>
                    <measurement group_id="O2" value="1.89" spread="1.337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any redness (&gt; 0 mm), post dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.32" spread="1.621"/>
                    <measurement group_id="O2" value="2.10" spread="2.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any swelling (&gt; 0 mm), post dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.39" spread="2.021"/>
                    <measurement group_id="O2" value="2.09" spread="1.273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any pain post-dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.96" spread="1.637"/>
                    <measurement group_id="O2" value="1.65" spread="0.775"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any redness (&gt; 0 mm), post dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.40" spread="2.191"/>
                    <measurement group_id="O2" value="1.77" spread="1.235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any swelling (&gt; 0 mm), post dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" spread="2.160"/>
                    <measurement group_id="O2" value="1.69" spread="1.251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any fever dose 1 (≥ 99.5°F ax or ≥ 100.4°F oral)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.45" spread="1.032"/>
                    <measurement group_id="O2" value="1.40" spread="0.707"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any nausea/vomiting, post dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.27" spread="0.719"/>
                    <measurement group_id="O2" value="1.43" spread="1.165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any diarrhea, post dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.89" spread="4.988"/>
                    <measurement group_id="O2" value="1.44" spread="1.044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any malaise, post dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.86" spread="1.324"/>
                    <measurement group_id="O2" value="1.74" spread="1.094"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any headache, post dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread="0.770"/>
                    <measurement group_id="O2" value="1.66" spread="1.328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any myalgia, post dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.72" spread="1.007"/>
                    <measurement group_id="O2" value="1.63" spread="1.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any fever dose 2 (≥ 99.5°F ax or ≥ 100.4°F oral)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread="0.577"/>
                    <measurement group_id="O2" value="1.00" spread="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any nausea/vomiting, post dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="0.000"/>
                    <measurement group_id="O2" value="1.20" spread="0.447"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any diarrhea, post dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" spread="0.816"/>
                    <measurement group_id="O2" value="2.20" spread="0.447"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any malaise, post dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.83" spread="1.602"/>
                    <measurement group_id="O2" value="1.71" spread="0.756"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any headache, post dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="0.000"/>
                    <measurement group_id="O2" value="1.30" spread="0.483"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any myalgia, post dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="1.528"/>
                    <measurement group_id="O2" value="1.54" spread="0.660"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Local and Systemic Solicited Symptoms, Cohort C</title>
        <time_frame>7 days after vaccination</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Afluria Cohort C</title>
            <description>Age 9 to &lt; 18 years</description>
          </group>
          <group group_id="O2">
            <title>Fluzone Cohort C</title>
            <description>Age 9 to &lt; 18 years</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Local and Systemic Solicited Symptoms, Cohort C</title>
          <population>Safety population</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="254"/>
                <count group_id="O2" value="250"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.96" spread="1.087"/>
                    <measurement group_id="O2" value="1.99" spread="1.136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any redness (&gt; 0 mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.02" spread="1.669"/>
                    <measurement group_id="O2" value="2.38" spread="1.992"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any swelling (&gt; 0 mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.75" spread="1.171"/>
                    <measurement group_id="O2" value="2.38" spread="1.724"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any fever (≥ 99.5°F ax or ≥ 100.4°F oral)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.82" spread="1.590"/>
                    <measurement group_id="O2" value="3.10" spread="2.644"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any nausea/vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.36" spread="0.569"/>
                    <measurement group_id="O2" value="2.88" spread="3.791"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.18" spread="0.395"/>
                    <measurement group_id="O2" value="1.36" spread="0.911"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.09" spread="1.487"/>
                    <measurement group_id="O2" value="2.82" spread="3.449"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.77" spread="1.443"/>
                    <measurement group_id="O2" value="2.05" spread="1.945"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.76" spread="1.100"/>
                    <measurement group_id="O2" value="2.11" spread="1.491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected for 180 days after the last study vaccination.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Afluria Cohort A</title>
          <description>Age 6 months to &lt; 3 years. Participants received one of two doses of the 2009/2010 influenza season formulation of Afluria.</description>
        </group>
        <group group_id="E2">
          <title>Afluria Cohort B</title>
          <description>Age 3 to &lt; 9 years. Participants received one or two doses of the 2009/2010 influenza season formulation of Afluria.</description>
        </group>
        <group group_id="E3">
          <title>Afluria Cohort C</title>
          <description>Age 9 to &lt; 18 years. Participants received one or two doses of the 2009/2010 influenza season formulation of Afluria.</description>
        </group>
        <group group_id="E4">
          <title>Fluzone Cohort A</title>
          <description>Age 6 months to &lt; 3 years. Participants received one of two doses of the 2009/2010 influenza season formulation of Fluzone.</description>
        </group>
        <group group_id="E5">
          <title>Fluzone Cohort B</title>
          <description>Age 3 to &lt; 9 years. Participants received one of two doses of the 2009/2010 influenza season formulation of Fluzone.</description>
        </group>
        <group group_id="E6">
          <title>Fluzone Cohort C</title>
          <description>Age 9 to &lt; 18 years. Participants received one of two doses of the 2009/2010 influenza season formulation of Fluzone.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="228"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Respiratory syncitial virus bronchiolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="210" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="216" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="214" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="187" subjects_at_risk="228"/>
                <counts group_id="E5" subjects_affected="202" subjects_at_risk="257"/>
                <counts group_id="E6" subjects_affected="202" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea/vomiting</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="228"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="24" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="63" subjects_at_risk="228"/>
                <counts group_id="E5" subjects_affected="27" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="25" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="228"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain at the injection site</sub_title>
                <counts group_id="E1" subjects_affected="107" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="157" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="167" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="89" subjects_at_risk="228"/>
                <counts group_id="E5" subjects_affected="134" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="151" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Redness at the injection site</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="60" subjects_at_risk="228"/>
                <counts group_id="E5" subjects_affected="67" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="43" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Swelling at the injection site</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="228"/>
                <counts group_id="E5" subjects_affected="50" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="41" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="42" subjects_at_risk="228"/>
                <counts group_id="E5" subjects_affected="29" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Loss of appetite</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="54" subjects_at_risk="228"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="142" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="99" subjects_at_risk="228"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E5" subjects_affected="37" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="51" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="69" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E5" subjects_affected="45" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="66" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="101" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E5" subjects_affected="66" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="93" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="228"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="228"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="228"/>
                <counts group_id="E5" subjects_affected="33" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="228"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="228"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Program Director</name_or_title>
      <organization>Seqirus</organization>
      <email>Seqirus.ClinicalTrials@Seqirus.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

